Data‐Independent Acquisition of HLA Class I Peptidomes on the Q Exactive Mass Spectrometer Platform. Issue 19 (9th October 2017)

• Record Type: Journal Article
• Authors: Ritz, Danilo; Kinzi, Jonny; Neri, Dario; Fugmann, Tim
• Is Part Of: Proteomics. Volume 17:Issue 19(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-10-09
• Subjects: antigens -- biomarker -- dia -- HLA peptidomics -- immunopeptidomics; Proteins -- Separation -- Periodicals; Bioinformatics -- Periodicals; Proteomics -- Periodicals; Genomes -- Periodicals; Molecular genetics -- Periodicals; 572.605
• DOI: 10.1002/pmic.201700177
• Languages: English
• ISSNs: 1615-9853

Abstract

Abstract: The characterization of peptides presented by human leukocyte antigen (HLA) class I molecules is crucial for understanding immune processes, biomarker discovery, and the development of novel immunotherapies or vaccines. Mass spectrometry allows the direct identification of thousands of HLA‐bound peptides from cell lines, blood, or tissue. In recent years, data‐independent acquisition (DIA) mass spectrometry methods have evolved, promising to increase reproducibility and sensitivity over classical data‐dependent acquisition (DDA) workflows. Here, we describe a DIA setup on the Q Exactive mass spectrometer, optimized regarding the unique properties of HLA class I peptides. The methodology enables sensitive and highly reproducible characterization of HLA peptidomes from individual cell lines. From up to 16 DDA analyses of 100 million human cells, more than 10 000 peptides could be confidently identified, serving as basis for the generation of spectral libraries. This knowledge enabled the subsequent interrogation of DIA data, leading to the identification of peptide sets with >90% overlap between replicate samples, a prerequisite for the comparative study of closely related specimens. Furthermore, >3000 peptides could be identified from just one million cells after DIA analysis using a library generated from 300 million cells. The reduction in sample quantity and the high reproducibility of DIA‐based HLA peptidome analysis should facilitate personalized medicine applications.